Eisai Co., Ltd.

OTCPK:ESAI.Y Stock Report

Market Cap: US$8.1b

Eisai Valuation

Is ESAI.Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ESAI.Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$8.23
Fair Value
13.2% undervalued intrinsic discount
15
Number of Analysts

Below Fair Value: ESAI.Y ($7.14) is trading below our estimate of fair value ($8.23)

Significantly Below Fair Value: ESAI.Y is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ESAI.Y?

Key metric: As ESAI.Y is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ESAI.Y. This is calculated by dividing ESAI.Y's market cap by their current earnings.
What is ESAI.Y's PE Ratio?
PE Ratio30.9x
EarningsJP¥40.97b
Market CapJP¥1.26t

Price to Earnings Ratio vs Peers

How does ESAI.Y's PE Ratio compare to its peers?

The above table shows the PE ratio for ESAI.Y vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.7x
JAZZ Jazz Pharmaceuticals
16x12.1%US$7.3b
ELAN Elanco Animal Health
29.1x1.6%US$6.0b
OGN Organon
3.2x-8.3%US$4.1b
CORT Corcept Therapeutics
46.5x34.7%US$6.2b
ESAI.Y Eisai
30.9x10.6%US$1.3t

Price-To-Earnings vs Peers: ESAI.Y is expensive based on its Price-To-Earnings Ratio (30.9x) compared to the peer average (23.7x).

Price to Earnings Ratio vs Industry

How does ESAI.Y's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.6xn/aUS$1.99b
KPRX Kiora Pharmaceuticals
2.1x20.7%US$11.61m
CNNC Cannonau
0.3xn/aUS$96.73k
SEEL.Q Seelos Therapeutics
0.00001xn/aUS$78.47k
ESAI.Y 30.9xIndustry Avg. 18.4xNo. of Companies6PE01224364860+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ESAI.Y is expensive based on its Price-To-Earnings Ratio (30.9x) compared to the US Pharmaceuticals industry average (18.6x).

Price to Earnings Ratio vs Fair Ratio

What is ESAI.Y's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ESAI.Y PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30.9x
Fair PE Ratio23.3x

Price-To-Earnings vs Fair Ratio: ESAI.Y is expensive based on its Price-To-Earnings Ratio (30.9x) compared to the estimated Fair Price-To-Earnings Ratio (23.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target
Consensus Narrative from 15 Analysts
US$9.14
Fair Value
21.9% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 06:07
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eisai Co., Ltd. is covered by 26 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Aaron HoCFRA Equity Research